MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Ketorolac Tromethamine 30 mg/mL Injection (Solution, 10 mL)	FIN	F 003 032

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Ketorolac Tromethamine, USP	0.300	g				
Benzyl Alcohol, NF	0.2	mL				
Sodium Chloride, USP	0.03	g				
Sterile Water for Injection, USP	9.0	mL				
Sterile Water for Injection, USP	q.s. to 10.0	mL				
Sodium Hydroxide 10% Solution	As required					
Hydrochloric Acid 10% Solution	As required					

MEDISCA® NETWORK INC.
TECHNICAL SUPPORT SERVICES
FORMULATION CHEMISTRY DEPARTMENT
TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

Suggested Formula	Ketorolac Tromethamine 30 mg/mL Injection (Solution, 10 mL)	FIN	F 003 032

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive *(protect from light whenever possible):* *Ketorolac Tromethamine*, *Benzyl Alcohol*

Suggested Preparatory Guidelines

☐ Non-Sterile Preparation ■ Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, sterility, pH and endotoxin testing considerations during preparation, it is suggested to measure an additional **20 to 25%** of the required quantities of ingredients.

Special Instruction: This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

Suggested Formula	Ketorolac Tromethamine 30 mg/mL Injection (Solution, 10 mL)	FIN	F 003 032

SUGGESTED PREPARATION (for 10 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Ketorolac Tromethamine, USP §	0.300	g			
Benzyl Alcohol, NF §	0.2	mL			
Sodium Chloride, USP §	0.03	g			
Sterile Water for Injection, USP §	9.0	mL			
Sterile Water for Injection, USP §	q.s. to 10.0	mL			
Sodium Hydroxide 10% Solution§	As required				
Hydrochloric Acid 10% Solution §	As required				

* Takes into account increased batch size conversions and density conversions, if required.
§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. **Equipment sterilization:**

   Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

Suggested Formula	Ketorolac Tromethamine 30 mg/mL Injection (Solution, 10 mL)	FIN	F 003 032

2. **Powder-Liquid preparation:**

A. Triturate the Ketorolac Tromethamine to form a fine, homogeneous powder.

B. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (9.0 mL *plus* processing error adjustments)

-Sodium Chloride
-Benzyl Alcohol
-Fine, homogeneous powder (Step 2A)

Specifications: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.

Note: Add the next ingredient, once the previous one has been completely added and dissolved.

Suggested Formula	Ketorolac Tromethamine 30 mg/mL Injection (Solution, 10 mL)	FIN	F 003 032

3.	**pH testing:** A. Draw an appropriate amount of the mixture (Step 2B). B. Test the pH of the sample. It should lie between 6.9 and 7.9. C. If the pH < 6.9, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% solution to the mixture: 1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% solution to the mixture. 2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% solution. 3. Re-test the pH. 4. Continue to add the Sodium Hydroxide 10% solution until the pH of 6.9 and 7.9 is obtained. IMPORTANT: Do not allow the pH to rise above 7.9. D. If the pH > 7.9, carefully add, in a dropwise fashion, the Hydrochloric Acid 10% solution to the mixture: 1. Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% solution to the mixture. 2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% solution. 3. Re-test the pH. 4. Continue to add the Hydrochloric Acid 10% solution until the pH of 6.9 and 7.9 is obtained. IMPORTANT: Do not allow the pH to fall below 6.9.
4.	**Filling to Volume:** A. Add additional Sterile Water for Injection to the above mixture to fill to the required batch size (10.0 mL *plus* processing error adjustments) Specifications: Continuously mix. End result: Homogeneous liquid-like solution.
5.	**Filtering and transferring:** Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.

Suggested Formula	Ketorolac Tromethamine 30 mg/mL Injection (Solution, 10 mL)	FIN	F 003 032

6.	**Filter integrity test:** Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
7.	**Sterility testing:** Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		14 days, refrigerated. BUD based on a successful sterility and endotoxin test result.	Packaging Requirements	Sterile, light-resistant unit dose injection vials.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	7	**Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.**
	2	Keep out of reach of children.	8	Discard in the presence of particulate matter.
	3	Equilibrate to room temperature before use.	9	Protect from light.
	4	Keep refrigerated. Do not freeze.	10	Discard container after use.
	5	**Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.**	11	**May impair mental and/or physical ability. Use care when operating a car or machinery.**
	6	Do not use if discolored.	12	Patient must avoid exposure to sunlight or artificial UV rays.
Pharmacist Instructions		Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.		
Patient Instructions		Contact your pharmacist in the event of adverse reactions.		

Suggested Formula	Ketorolac Tromethamine 30 mg/mL Injection (Solution, 10 mL)	FIN	F 003 032

REFERENCES

1. USP <797> Pharmaceutical Compounding – Sterile Preparations. US Pharmacopeial Convention, Inc. *United States Pharmacopeia XXVIII / National Formulary 23.* Rockville, MD. 2004: 2461.
2. Parenteral Preparations. In: Allen, LV, Jr. *The Art, Science and Technology of Pharmaceutical Compounding.* American Pharmaceutical Association; 1998: 251.
3. Ketorolac Tromethamine Injection USP. In: Canadian Pharmacists Association. *Compendium of Pharmacists and Specialties, 2007.* 1237.
4. Sodium Chloride. In: Rowe RC. *Handbook of Pharmaceutical Excipients, 4th Edition.* American Pharmaceutical Association; 2003: 556.
5. Benzyl Alcohol. In: Rowe RC. *Handbook of Pharmaceutical Excipients, 4th Edition.* American Pharmaceutical Association; 2003: 53.
6. Ketorolac Trometamol. In: Sweetman SC, ed. *Martindale: The Complete Drug Reference, 34th Edition.* London, England: The Pharmaceutical Press; 2005: 52.
7. Ketorolac (Monograph). In: O'Neil MJ. *The Merck Index 14th Edition.* Whitehouse Station, NJ: Merck & Co, Inc.; 2006: #5306.
8. Ketorolac Tromethamine. In: Trissel LA. *Trissel's Stability of Compounded Formulations, 3rd Edition.* American Pharmaceutical Association; 2005: 241.
9. Ketorolac Systemic. Thomson Micromedex. *USP DI – Drug Information for the Health Care Professional, 26th Edition.* Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1838.
10. Ketorolac Tromethamine (Monograph). *United States Pharmacopeia XXVIII / National Formulary 23.* Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 1100.
11. Chapter 8: Buffered and Isotonic Solutions. In: Martin, A. *Physical Pharmacy, Fourth Edition.* Philadelphia, PA: Lipponcott Williams & Wilkins; 1993: 169~189.
12. Chapter 18: Tonicity, Osmoticity, Osmolaltiy and Osmolarity. In: Gennaro AR. *Remington: The Science and Practice of Pharmacy, 20th Edition.* Baltimore, MD: Lippincott Williams & Wilkins; 2000: 246~262.